RANKL biology: bone metabolism, the immune system, and beyond
Abstract Receptor activator of NF-κB (RANK) ligand (RANKL) induces the differentiation of monocyte/macrophage–lineage cells into the bone–resorbing cells called osteoclasts. Because abnormalities in RANKL, its signaling receptor RANK, or decoy receptor osteoprotegerin (OPG) lead to bone diseases suc...
Main Authors: | Takehito Ono, Mikihito Hayashi, Fumiyuki Sasaki, Tomoki Nakashima |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-02-01
|
Series: | Inflammation and Regeneration |
Subjects: | |
Online Access: | https://doi.org/10.1186/s41232-019-0111-3 |
Similar Items
-
Targeting the RANKL/RANK/OPG Axis for Cancer Therapy
by: Jie Ming, et al.
Published: (2020-08-01) -
Bone metabolism and RANKL/RANK/OPG trail in periodontal disease
by: Czupkallo Lukasz, et al.
Published: (2016-12-01) -
Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications
by: Sarvraj Singh Kohli, et al.
Published: (2011-01-01) -
Role of periodontal pathogenic bacteria in RANKL-mediated bone destruction in periodontal disease
by: Mikihito Kajiya, et al.
Published: (2010-11-01) -
Current Understanding of Osteoimmunology in Certain Osteoimmune Diseases
by: Anqi Zhou, et al.
Published: (2021-08-01)